Neomorph develops molecular glue degraders and has built a proprietary platform to engineer neomorphic protein surfaces that enable targeted protein degradation of disease drivers previously considered undruggable. Its lead investigational candidate, NEO‑811, is designed to induce degradation of ARNT (HIF‑1β) and is being evaluated in a first‑in‑human Phase 1/2 open‑label monotherapy trial in patients with locally advanced or metastatic non‑resectable clear cell renal cell carcinoma. The company says its platform spans multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases, creating what it calls the world’s largest proprietary molecular glue target space. Neomorph has partnerships with pharmaceutical companies including Novo Nordisk, Biogen, and AbbVie across cardiometabolic disease, rare disease, neurology, oncology, and immunology. The company plans to use the $100 million Series B to advance NEO‑811 through clinical development and to progress its broader pipeline across multiple therapeutic areas. Neomorph was founded in 2020 and is headquartered in San Diego.

Total raised

$209M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2026